Neurology/Psychiatric July 12, 2023 Novartis AG has described pyridine-3-carboxylate compounds acting as voltage-dependent L-type calcium channel subunit -1C channel (Cav1.2) activators reported to be useful for the treatment of schizophrenia, major depression, attention deficit hyperactivity disorder, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimers disease and Brugada syndrome
Use of the RFVA system for the PIMA procedure is investigational
Regular monitoring is essential when taking this combination
Reasons for Discontinuing GLP-1 Use Lapsed weight loss users said price and insurance coverage were the top reasons for discontinuing use
[1] [2] Whilst primarily recognised for its metabolic effects, research suggests Saxenda may influence the central nervous system, particularly in regions governing appetite regulation and energy homeostasis
weight management